Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2011-05-27

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbrc.2011.04.108PMID 21549095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased Affinity to Canalicular P-gp via Formation of Lipophilic Ion-Pair Complexes with Endogenous Bile Salts is Associated with Mw Threshold in Hepatobiliary Excretion of Quaternary Ammonium Compounds

  2010cited by this paper
• Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human

  2009cited by this paper
• Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

  2008cited by this paper
• Topoisomerase I Protein Expression and Prognosis of Patients with Colorectal Cancer

  2007cited by this paper
• Novel small molecule induces p53-dependent apoptosis in human colon cancer cells.

  2007cited by this paper
• Topoisomerase I inhibitors: camptothecins and beyond

  2006cited by this paper
• Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.

  2006cited by this paper
• The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor

  2004cited by this paper
• Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

  2004cited by this paper
• Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

  2003cited by this paper
• Drug discovery and p53.

  2003cited by this paper
• Isodiospyrin as a novel human DNA topoisomerase I inhibitor.

  2003cited by this paper
• Cellular roles of DNA topoisomerases: a molecular perspective

  2002cited by this paper
• P53: An ubiquitous target of anticancer drugs

  2002cited by this paper
• Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

  2001cited by this paper
• Tumor cell death induced by topoisomerase-targeting drugs.

  2001cited by this paper
• Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.

  2000cited by this paper
• BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.

  2000cited by this paper
• Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

  2000cited by this paper
• Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain*

  1998cited by this paper
• The complexity of p53 modulation: emerging patterns from divergent signals.

  1998cited by this paper
• DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

  1997cited by this paper
• p53; from inductive signal to cellular effect.

  1997cited by this paper
• Genetic studies and molecular markers of bladder cancer.

  1997cited by this paper
• DNA topoisomerases.

  1996cited by this paper
• p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

  1996cited by this paper
• Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

  1996cited by this paper
• p53 in growth control and neoplasia.

  1996cited by this paper
• Eukaryotic DNA topoisomerases I.

  1995cited by this paper
• The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

  1994cited by this paper
• Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

  1994cited by this paper
• The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B.

  1992cited by this paper
• Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.

  1989cited by this paper
• DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

  1989cited by this paper
• Localization of the active type I DNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23-24 and 22q11.2-13.1

  1989cited by this paper
• Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

  1989cited by this paper

• Investigational DNA topoisomerase I inhibitors for colorectal cancer: preclinical and early phase developments

  2025cites this paper
• Cirsiliol suppresses the proliferation of human oral cancer cells by targeting topoisomerase I

  2025cites this paper
• Metabolomics insights into doxorubicin and 5-fluorouracil combination therapy in triple-negative breast cancer: a xenograft mouse model study

  2025cites this paper
• Camptothecin 20(S)-sulfonyl amidine derivative inhibits gastric cancer cell proliferation by targeting topoisomerase I to trigger the DNA damage-apoptosis cascade.

  2025cites this paper
• Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

  2022cites this paper
• Current scenario of indole derivatives with potential anti-drug-resistant cancer activity.

  2020cites this paper
• Induction of G2/M Phase Arrest by Diosgenin via Activation of Chk1 Kinase and Cdc25C Regulatory Pathways to Promote Apoptosis in Human Breast Cancer Cells

  2019cites this paper
• Protopine isolated from Nandina domestica induces apoptosis and autophagy in colon cancer cells by stabilizing p53

  2019cites this paper
• Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems.

  2019cites this paper
• Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?

  2018cites this paper
• Activation of the p53 pathway with digiferrol isolated from Rubia philippinensis induces cell cycle arrest, apoptosis, and autophagy in colon cancer cells.

  2018cites this paper
• Inhibition of MDR 1 in Mammary Cell Carcinoma Reverses Multidrug Resistance by SOCS 1

  2016cites this paper
• Activation of p53 with Ilimaquinone and Ethylsmenoquinone, Marine Sponge Metabolites, Induces Apoptosis and Autophagy in Colon Cancer Cells

  2015cites this paper
• Down Regulation of CIAPIN1 Reverses Multidrug Resistance in Human Breast Cancer Cells by Inhibiting MDR1

  2012cites this paper